Phathom Pharmaceuticals, Inc.

Fundamentals4.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High gross margins
  • Severe cash burn
  • Heavy long-term debt

AI
AI Summary

6.0

PHAT has materially shifted from a cash‑burn developer to a commercial‑stage company where high VOQUEZNA gross margins and rapid script growth make operating profitability by Q3/FY2026 plausible, meaning the investment now hinges on execution and near‑term cash‑flow delivery rather than pure pipeline binary. The key actionable monitorables are sustained positive free cash flow and continued GI script momentum coupled with visible debt mitigation (paydown, covenant relief, or credible refinancing) — failure on any of these would likely force dilution or distress.

Execution
Refinancing
Commercialization‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • High gross margins
  • Severe cash burn
  • Heavy long-term debt

PHAT combines very high gross margins with crippling operating losses, heavy long-term debt and deep cash burn that make solvency the primary near-term risk.

risk
margin

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Mild downtrend
  • Support held bounce
  • Volatility spike

Price action over the last month was mildly negative and rangebound, sliding from $11.42 to $11.21 with support at $10.22 and resistance near $11.4–$11.5 (stronger at $12.5–$13.6), after a ~25% swing from the February highs that raises short-term volatility and downside risk until a breakout above the higher resistance band.

bearish
rangebound
Support Level: $10.22 (secondary $10.67)
Resistance Level: $11.40–$11.50; stronger $12.50–$13.60

~25% swing from $13.56 to $10.22 last month indicating elevated short-term volatility

Sentiment & News

7.0

Key News Insights:

  • Revenue acceleration
  • Near‑term profitability
  • Active investor outreach

Phathom reports strong commercial momentum for VOQUEZNA, sharply rising FY‑2025 revenue and improved GAAP loss, while expecting operating profitability in 2026 and ramping investor outreach.

VOQUEZNA

These results and guidance reduce near‑term financial risk and, combined with balance‑sheet strengthening and outreach, should support stock sentiment as commercialization scales